Osmotica is committed to bringing generic products that are difficult to develop and manufacture to market. We leverage our significant technological know-how to develop products that require complicated delivery systems and can bring products to market that other generic companies simply can't. With a robust pipeline, our generic products division is growing quickly and remains dedicated to providing quality products backed by the vast resources of our global infrastructure.
With a particular focus on the CNS therapeutic category, Osmotica is employing our patented delivery systems and intellectual property to develop branded pharmaceutical products for the global patient population. Through innovation and our unique technologies, we are developing both osmotic and non-osmotic products for commercial distribution.
Osmotica brings a strong track record of resolving challenging drug delivery issues, evidenced by the products that are currently marketed by our partners around the world. These represent successful development of both soluble and insoluble drugs, combination products and technology applications across diverse therapeutic areas.
Osmotica's Research and Development Pipeline maximizes the synergies of the Company's expertise, capacity and intellectual property. Our pipeline is divided into three distinct categories:
An internal proprietary development program focused on new and improved treatments for CNS disorders. Our R&D pipeline targets unmet medical and commercial needs.
Leveraging our core capabilities to develop partnered products for commercialization outside our therapeutic focus. These products often include challenging development hurdles that require our type of specialized expertise.
Innovation that enhances the scope of our current drug delivery solutions. Our technology pipeline includes continued advances and improvements to the Osmodex® technologies as well as other controlled-release delivery technologies.